Leerink Partnrs Estimates AxoGen's Q2 Earnings (NASDAQ:AXGN)

AxoGen, Inc. (NASDAQ:AXGN - Free Report) - Leerink Partnrs dropped their Q2 2025 earnings per share estimates for shares of AxoGen in a research report issued to clients and investors on Monday, July 14th. Leerink Partnrs analyst M. Kratky now forecasts that the medical equipment provider will post earnings of ($0.04) per share for the quarter, down from their prior estimate of ($0.02). The consensus estimate for AxoGen's current full-year earnings is ($0.29) per share. Leerink Partnrs also issued estimates for AxoGen's FY2025 earnings at ($0.14) EPS, FY2027 earnings at $0.14 EPS, FY2028 earnings at $0.24 EPS and FY2029 earnings at $0.35 EPS.

Separately, Canaccord Genuity Group cut their target price on AxoGen from $26.00 to $24.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, AxoGen presently has an average rating of "Buy" and a consensus price target of $24.50.

AxoGen Price Performance

Shares of AXGN traded down $0.35 during midday trading on Thursday, reaching $11.28. The stock had a trading volume of 676,057 shares, compared to its average volume of 518,928. AxoGen has a 52 week low of $7.34 and a 52 week high of $21.00. The company has a debt-to-equity ratio of 0.63, a current ratio of 4.28 and a quick ratio of 2.65. The firm's 50 day moving average price is $10.92 and its 200-day moving average price is $15.11. The company has a market capitalization of $513.69 million, a P/E ratio of -75.19 and a beta of 1.04.

Institutional Investors Weigh In On AxoGen

A number of hedge funds and other institutional investors have recently made changes to their positions in AXGN. US Bancorp DE acquired a new position in shares of AxoGen during the 4th quarter valued at about $30,000. Charles Schwab Investment Management Inc. increased its holdings in shares of AxoGen by 14.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 416,610 shares of the medical equipment provider's stock valued at $6,866,000 after acquiring an additional 52,846 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of AxoGen during the 4th quarter valued at about $4,552,000. Intech Investment Management LLC increased its holdings in shares of AxoGen by 33.6% during the 4th quarter. Intech Investment Management LLC now owns 16,456 shares of the medical equipment provider's stock valued at $271,000 after acquiring an additional 4,141 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd acquired a new position in shares of AxoGen during the 4th quarter valued at about $93,000. 80.29% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at AxoGen

In other news, Director Joseph A. Tyndall sold 20,062 shares of the firm's stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $11.20, for a total transaction of $224,694.40. Following the completion of the sale, the director directly owned 15,345 shares of the company's stock, valued at $171,864. This trade represents a 56.66% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 2.78% of the stock is owned by company insiders.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.